What are the Side Effects
We are committed to helping you make the most of your semaglutide GLP-1 treatment for long-term success
Specific Populations No clinically significant differences in semaglutide pharmacokinetics were observed based on age (18 years old), sex, race (White, Asian or Black or African American), ethnicity, body weight (40 to 188 kg), upper GI disease (i.e., chronic gastritis and/or gastroesophageal reflux disease), hepatic impairment (i.e., mild, moderate, severe based on the Child-Pugh system) and renal impairment (i.e., mild, moderate, severe, end staged renal disease)
For telemedicine providers only: Please upload a spreadsheet (use this template ) to help us understand how your telemedicine practice complies with applicable laws and regulations